⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

Official Title: Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial.

Study ID: NCT05538689

Study Description

Brief Summary: In this project, the proposition is that the use of daily dosed Myfembree ( a combination of relugolix with estradiol and norethindrone acetate), FDA-approved medication to treat heavy menses fibroid-related symptoms, has the potential to delay the recurrence of fibroid symptoms, prolong the improved quality of life and delay the need for re-intervention after uterine sparing surgery versus the routine standard of care.

Detailed Description:

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: Yes

Locations

University of Chicago South Loop, Chicago, Illinois, United States

University of Chicago River East, Chicago, Illinois, United States

University of Chicago DCAM, Chicago, Illinois, United States

University of Chicago Flossmoor, Flossmoor, Illinois, United States

University of Chicago Orland Park, Orland Park, Illinois, United States

University of Chicago Schererville, Schererville, Indiana, United States

Contact Details

Name: Obianuju Sandra Madueke Laveaux, MD MPH

Affiliation: University of Chicago

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: